CAR-T and other adoptive cell therapies for B cell malignancies

Jain, 2018, Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib, Br J Haematol, 183, 578, 10.1111/bjh.15567 Martin, 2016, Postibrutinib outcomes in patients with mantle cell lymphoma, Blood, 127, 1559, 10.1182/blood-2015-10-673145 Epperla, 2017, Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study, Hematol Oncol, 35, 528, 10.1002/hon.2380 Xu, 2019, Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies, Front Immunol, 10, 2664, 10.3389/fimmu.2019.02664 Jain, 2020, Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL, Blood Adv, 4, 1038, 10.1182/bloodadvances.2019001396 Kochenderfer, 2013, Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors, Nat Rev Clin Oncol, 10, 267, 10.1038/nrclinonc.2013.46 Maude, 2016, Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis, Blood, 128, 10.1182/blood.V128.22.2801.2801 Schuster, 2019, Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980 Neelapu, 2017, Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Wang, 2020, KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma, N Engl J Med, 382, 1331, 10.1056/NEJMoa1914347 Abramson, 2019, Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas, Blood, 134, 241, 10.1182/blood-2019-127508 George, 2020, Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE), BMJ Open, 10, e034629, 10.1136/bmjopen-2019-034629 Enblad, 2018, A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia, Clin Cancer Res, 24, 6185, 10.1158/1078-0432.CCR-18-0426 Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226 Hou, 2021, Navigating CAR-T cells through the solid-tumour microenvironment, Nat Rev Drug Discov, 20, 531, 10.1038/s41573-021-00189-2 Yu, 2019, Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity, Mol Cancer, 18, 125, 10.1186/s12943-019-1057-4 Ramos, 2018, In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas, Mol Ther, 26, 2727, 10.1016/j.ymthe.2018.09.009 Schubert, 2019, Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients, Blood, 134, 51, 10.1182/blood-2019-125423 Wang, 2020, Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies, Blood, 135, 17, 10.1182/blood.2019000017 Yang, 2019, Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia, Blood, 134 Zhang, 2018, Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy, J Hematol Oncol, 11, 10.1186/s13045-018-0646-9 Han, 2019, Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy, J Hematol Oncol, 12, 128, 10.1186/s13045-019-0813-7 Pan, 2020, Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL, Blood, 135, 387, 10.1182/blood.2019003293 Zah, 2016, T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells, Cancer Immunol Res, 4, 498, 10.1158/2326-6066.CIR-15-0231 Dai, 2020, Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia, J Hematol Oncol, 13, 30, 10.1186/s13045-020-00856-8 Cao, 2019, Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma, Front Oncol, 9, 767, 10.3389/fonc.2019.00767 Liu, 2019, A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma, J Clin Oncol, 37, 7557, 10.1200/JCO.2019.37.15_suppl.7557 Shah, 2020, Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial, Nat Med, 26, 1569, 10.1038/s41591-020-1081-3 Gattinoni, 2005, Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells, J Exp Med, 202, 907, 10.1084/jem.20050732 Corrigan-Curay, 2014, T-cell immunotherapy: looking forward, Mol Ther, 22, 1564, 10.1038/mt.2014.148 Neelapu, 2019, CAR-T efficacy: is conditioning the key?, Blood, 133, 1799, 10.1182/blood-2019-03-900928 Shah, 2021, KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study, Lancet, 398, 491, 10.1016/S0140-6736(21)01222-8 Maude, 2018, Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Yang, 2019, A Feasibility and Safety Study of a New CD19-Directed Fast CAR-T Therapy for Refractory and Relapsed B Cell Acute Lymphoblastic Leukemia, Blood, 134 Park, 2018, Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919 Abramson, 2020, Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study, The Lancet, 396, 839, 10.1016/S0140-6736(20)31366-0 Wang, 2019, Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001, J Clin Oncol, 37, 7516, 10.1200/JCO.2019.37.15_suppl.7516 Jacobson, 2020, Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), J Clin Oncol, 38, 8008, 10.1200/JCO.2020.38.15_suppl.8008 Wang, 2017, Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial, Clin Cancer Res, 23, 1156, 10.1158/1078-0432.CCR-16-1365 Ramos, 2020, Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma, J Clin Oncol, 38, 3794, 10.1200/JCO.20.01342 Wang, 2018, Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma, Clin Cancer Res, 24, 106, 10.1158/1078-0432.CCR-17-0344 Bertilaccio, 2014, Combining CD23 chimeric antigen receptor immunotherapy and lenalidomide as a novel therapeutic strategy for chronic lymphocytic leukemia, Cytotherapy, 16, S35, 10.1016/j.jcyt.2014.01.119 Ruella, 2016, The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma, Clin Cancer Res, 22, 2684, 10.1158/1078-0432.CCR-15-1527 Qin, 2020, Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib, J Immunother, 43, 107, 10.1097/CJI.0000000000000307 Gauthier, 2020, Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure, Blood, 135, 1650, 10.1182/blood.2019002936 Wang, 2020, KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma, N Engl J Med, 382, 1331, 10.1056/NEJMoa1914347 Lefebvre, 2019, 16207: Cardiovascular Effects of Chimeric Antigen Receptor T-Cell (CART Cell) Therapy in Adults, Circulation, 140 Chen, 2016, Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy, J Immunol Methods, 434, 1, 10.1016/j.jim.2016.03.005 Mehta, 2020, Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome, Lancet Rheumatol, 2, e358, 10.1016/S2665-9913(20)30096-5 Strati, 2020, Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma, Blood Adv, 4, 3123, 10.1182/bloodadvances.2020002328 Jacobson, 2018, CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma, J Clin Oncol, 37, 328, 10.1200/JCO.18.01457 Neelapu, 2018, Chimeric antigen receptor T-cell therapy — assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148 Vitale, 2020, CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences, Front Oncol, 10, 849, 10.3389/fonc.2020.00849 Topp, 2019, Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma, Blood, 134, 10.1182/blood-2019-126081 MLea, 2020, Management of a Patient with Mantle Cell Lymphoma who Developed Severe Neurotoxicity After tChimeric Antigen Receptor T-Cell Therapy in ZUMA-2, J Immunother Cancer, 8, e001114, 10.1136/jitc-2020-001114 Parker, 2020, Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies, Cell, 183, 10.1016/j.cell.2020.08.022 Duong, 2018, Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches, Mol Ther Oncolytics, 12, 124, 10.1016/j.omto.2018.12.009 Rezvani, 2017, Engineering Natural Killer Cells for Cancer Immunotherapy, Mol Ther, 25, 1769, 10.1016/j.ymthe.2017.06.012 Westin, 2019, Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial, Blood, 134, 10.1182/blood-2019-129107 Dean, 2019, Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma, J Clin Oncol, 37, 7562, 10.1200/JCO.2019.37.15_suppl.7562 Wei, 2020, The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma, Signal Transduct Target Ther, 5, 134, 10.1038/s41392-020-00256-x Zhang, 2020, Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy, J Immunother Cancer, 8, e001150, 10.1136/jitc-2020-001150 Locke, 2020, Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma, Blood Adv, 4, 4898, 10.1182/bloodadvances.2020002394 Jacobson, 2020, Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity, J Clin Oncol, 38, 3095, 10.1200/JCO.19.02103 Deng, 2020, Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas, Nat Med, 26, 1878, 10.1038/s41591-020-1061-7 Liu, 2020, Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors, N Engl J Med, 382, 545, 10.1056/NEJMoa1910607 Yamamoto, 2019, Developing neoantigen-targeted T cell-based treatments for solid tumors, Nat Med, 25, 1488, 10.1038/s41591-019-0596-y Chrusciel, 2020, Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours, Cancers (Basel), 12, 10.3390/cancers12030683 Boon, 1996, Human tumor antigens recognized by T lymphocytes, J Exp Med, 183, 725, 10.1084/jem.183.3.725 Morris, 2016, Optimizing T-cell receptor gene therapy for hematologic malignancies, Blood, 127, 3305, 10.1182/blood-2015-11-629071 Garber, 2018, Driving T-cell immunotherapy to solid tumors, Nat Biotechnol, 36, 215, 10.1038/nbt.4090 Hughes, 2005, Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions, Hum Gene Ther, 16, 457, 10.1089/hum.2005.16.457 Rapoport, 2015, NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma, Nat Med, 21, 914, 10.1038/nm.3910 D'Angelo, 2018, Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma, Cancer Discov, 8, 944, 10.1158/2159-8290.CD-17-1417 Hunder, 2008, Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, N Engl J Med, 358, 2698, 10.1056/NEJMoa0800251 Johnson, 2006, Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, J Immunol, 177, 6548, 10.4049/jimmunol.177.9.6548 Deniger, 2016, Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System, Mol Ther, 24, 1078, 10.1038/mt.2016.51 Malekzadeh, 2020, Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens, Clin Cancer Res, 26, 1267, 10.1158/1078-0432.CCR-19-1874 Mayr, 2006, MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes, Exp Hematol, 34, 44, 10.1016/j.exphem.2005.09.016 Goodridge, 2019, FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies, Blood, 134, 301, 10.1182/blood-2019-129319 Kloss, 2018, Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication, Mol Ther, 26, 1855, 10.1016/j.ymthe.2018.05.003 Tang, 2020, TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors, JCI Insight, 5, e133977, 10.1172/jci.insight.133977 Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol, 20, 31, 10.1016/S1470-2045(18)30864-7